Janux Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Janux Therapeutics, Inc. (JANX) reported Increase (Decrease) in Accounts Payable of -$1.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$342.00K, a 130.73% decline year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.61M.
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.67M, a 7.06% increase year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$168.00K, a 114.30% decline year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $977.00K, a 38.32% decline from fiscal 2024.
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.58M, a 471.84% increase from fiscal 2023.
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $277.00K.
- Janux Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$294.00K, a 113.74% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.95M 10-Q · filed 2026-08-06 | -$285.00K derived: sum of 3 quarters · filed 2026-08-06 | -$453.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.61M 10-Q · filed 2026-05-07 | $57.00K derived: sum of 2 quarters · filed 2026-05-07 | -$111.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.50M derived: sum of 2 quarters · filed 2026-02-26 | $2.61M derived: sum of 3 quarters · filed 2026-08-06 | $977.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $945.00K derived: sum of 2 quarters · filed 2026-08-06 | -$692.00K 10-Q · filed 2025-11-06 | $867.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$524.00K 10-Q · filed 2026-08-06 | $1.03M derived: sum of 3 quarters · filed 2026-08-06 | $2.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.64M 10-Q · filed 2026-05-07 | -$78.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.10M derived: sum of 3 quarters · filed 2026-05-07 | $403.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.73M derived: sum of 2 quarters · filed 2026-02-26 | $2.04M derived: sum of 3 quarters · filed 2026-02-26 | $1.58M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $481.00K derived: sum of 2 quarters · filed 2025-11-06 | $25.00K 10-Q · filed 2025-11-06 | $352.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$694.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.15M 10-Q · filed 2025-08-07 | -$823.00K derived: sum of 3 quarters · filed 2026-02-26 | -$595.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$456.00K 10-Q · filed 2025-05-08 | -$129.00K derived: sum of 2 quarters · filed 2026-02-26 | $99.00K derived: sum of 3 quarters · filed 2026-02-26 | -$72.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $555.00K derived: sum of 2 quarters · filed 2026-02-26 | $384.00K derived: sum of 3 quarters · filed 2026-02-26 | $277.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $57.00K derived: sum of 2 quarters · filed 2024-11-06 | -$50.00K 10-Q · filed 2024-11-06 | $173.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$278.00K 10-Q · filed 2024-08-07 | -$55.00K derived: sum of 3 quarters · filed 2025-02-27 | -$689.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$107.00K 10-Q · filed 2024-05-08 | $116.00K derived: sum of 2 quarters · filed 2025-02-27 | -$518.00K derived: sum of 3 quarters · filed 2025-02-27 | $339.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$411.00K derived: sum of 2 quarters · filed 2025-02-27 | $446.00K derived: sum of 3 quarters · filed 2025-02-27 | -$294.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | -$634.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $223.00K derived: sum of 2 quarters · filed 2023-11-07 | -$517.00K 10-Q · filed 2023-11-07 | -$999.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $857.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $117.00K 10-Q · filed 2023-08-08 | -$365.00K derived: sum of 3 quarters · filed 2023-08-08 | $2.22M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$740.00K 10-Q · filed 2023-05-09 | -$1.22M derived: sum of 2 quarters · filed 2023-05-09 | $1.36M derived: sum of 3 quarters · filed 2023-05-09 | $1.05M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $2.10M derived: sum of 2 quarters · filed 2023-03-10 | $1.79M derived: sum of 3 quarters · filed 2023-03-10 | $2.14M 10-K · filed 2023-03-10 |
| 2021-09-30 | $2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.27M derived: sum of 2 quarters · filed 2022-11-10 | $2.62M 10-Q · filed 2022-11-10 | $2.42M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$310.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $37.00K 10-Q · filed 2022-08-09 | -$161.00K derived: sum of 3 quarters · filed 2022-08-09 | -$116.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $347.00K 10-Q · filed 2022-05-10 | $149.00K derived: sum of 2 quarters · filed 2022-05-10 | $194.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$153.00K derived: sum of 2 quarters · filed 2022-03-18 | $14.00K 10-K · filed 2022-03-18 | |
| 2020-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $212.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $167.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |